🇺🇸 FDA
Patent

US 10695304

Dosage forms and methods for enantiomerically enriched or pure bupropion

granted A61KA61K31/137

Quick answer

US patent 10695304 (Dosage forms and methods for enantiomerically enriched or pure bupropion) held by AXSOME THERAPEUTICS, INC. expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
AXSOME THERAPEUTICS, INC.
Grant date
Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/137